195 related articles for article (PubMed ID: 1286308)
1. [Serum tumor markers SCC, TATI and TPS: value in follow-up of females with cervix cancer].
Joura E; Gitsch G; Kainz C; Fröhlich B; Biegelmayr C; Kölbl H
Gynakol Geburtshilfliche Rundsch; 1992; 32 Suppl 1():115. PubMed ID: 1286308
[No Abstract] [Full Text] [Related]
2. Squamous cell carcinoma antigen, tumor associated trypsin inhibitor and tissue polypeptide specific antigen in follow up of stage III cervical cancer.
Gitsch G; Kainz C; Joura E; Fröhlich B; Bieglmayr C; Tatra G
Anticancer Res; 1992; 12(4):1247-9. PubMed ID: 1503417
[TBL] [Abstract][Full Text] [Related]
3. Squamous cell carcinoma antigen, tumor-associated trypsin inhibitor, and carcinoembryonic antigen for monitoring cervical cancer.
Pectasides D; Economides N; Bourazanis J; Pozadzizou P; Gogou L; Koutsiouba P; Athanassiou A
Am J Clin Oncol; 1994 Aug; 17(4):307-12. PubMed ID: 8048392
[TBL] [Abstract][Full Text] [Related]
4. Early predicting recurrent cervical cancer with combination of tissue polypeptide specific antigen (TPS) and squamous cell carcinoma antigen (SCC).
Hung YC; Shiau YC; Chang WC; Kao CH; Lin CC
Neoplasma; 2002; 49(6):415-7. PubMed ID: 12584591
[TBL] [Abstract][Full Text] [Related]
5. [Detection of recurrent cervix cancer with serum SCC measurement?].
Bittl A; Böhm M; Kastner P; Di Paolo M; Jäger W
Gynakol Geburtshilfliche Rundsch; 1993; 33 Suppl 1():228. PubMed ID: 8118284
[No Abstract] [Full Text] [Related]
6. Tissue polypeptide specific antigen and squamous cell carcinoma antigen for early prediction of recurrence in lung squamous cell carcinoma.
Ho YJ; Hsieh JF; Tasi SC; Lee JK; Kao CH
Lung; 2000; 178(2):75-80. PubMed ID: 10773133
[TBL] [Abstract][Full Text] [Related]
7. Tissue polypeptide specific antigen in the follow-up of ovarian and cervical cancer patients.
Tempfer C; Hefler L; Haeusler G; Reinthaller A; Koelbl H; Zeisler H; Kainz C
Int J Cancer; 1998 Jun; 79(3):241-4. PubMed ID: 9645344
[TBL] [Abstract][Full Text] [Related]
8. TPA, TATI, CEA, AFP, beta-HCG, PSA, SCC, and CA 19-9 for monitoring transitional cell carcinoma of the bladder.
Pectasides D; Bafaloucos D; Antoniou F; Gogou L; Economides N; Varthalitis J; Dimitriades M; Kosmidis P; Athanassiou A
Am J Clin Oncol; 1996 Jun; 19(3):271-7. PubMed ID: 8638540
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of squamous cell carcinoma antigen in cancer of the human uterine cervix. Comparison with CEA and CA-125.
Verlooy H; Devos P; Janssens J; Mortelmans L; Gerits M; Bonte J; De Roo M
Gynecol Obstet Invest; 1991; 32(1):55-8. PubMed ID: 1765320
[TBL] [Abstract][Full Text] [Related]
10. The Diagnostic and Prognostic Value of Tumor Markers (CEA, SCC, CYFRA 21-1, TPS) in Head and Neck Cancer Patients.
Barak V; Meirovitz A; Leibovici V; Rachmut J; Peretz T; Eliashar R; Gross M
Anticancer Res; 2015 Oct; 35(10):5519-24. PubMed ID: 26408719
[TBL] [Abstract][Full Text] [Related]
11. Renal function and serum concentration of five tumor markers (TATI, SCC, CYFRA 21-1, TPA, and TPS) in patients without evidence of neoplasia.
Tramonti G; Ferdeghini M; Donadio C; Norpoth M; Annichiarico C; Bianchi R; Bianchi C
Cancer Detect Prev; 2000; 24(1):86-90. PubMed ID: 10757127
[TBL] [Abstract][Full Text] [Related]
12. [SCC (squamous cell carcinoma) antigen as a tumor marker in cervix cancers].
Geyer H; Schwörer D; Pfleiderer A
Geburtshilfe Frauenheilkd; 1989 Mar; 49(3):266-71. PubMed ID: 2721888
[TBL] [Abstract][Full Text] [Related]
13. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P
Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246
[TBL] [Abstract][Full Text] [Related]
14. The curative role of radiotherapy in patients with isolated para-aortic node recurrence from cervical cancer and value of squamous cell carcinoma antigen for early detection.
Ogino I; Nakayama H; Kitamura T; Okamoto N; Inoue T
Int J Gynecol Cancer; 2005; 15(4):630-8. PubMed ID: 16014117
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of preoperative serum squamous cell carcinoma antigen (SCC-Ag) level on tumor recurrence in cervical squamous cell carcinoma patients treated with radical surgery: A single-institution study.
Guo Q; Zhu J; Wu Y; Wen H; Xia L; Wu X; Ju X
Eur J Surg Oncol; 2020 Jan; 46(1):131-138. PubMed ID: 31481274
[TBL] [Abstract][Full Text] [Related]
16. Squamous cell carcinoma antigen and cancer antigen 125 in southern Indian cervical cancer patients.
Porika M; Vemunoori AK; Tippani R; Mohammad A; Bollam SR; Abbagani S
Asian Pac J Cancer Prev; 2010; 11(6):1745-7. PubMed ID: 21338226
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment serum squamous cell carcinoma antigen: a newly identified prognostic factor in early-stage cervical carcinoma.
Duk JM; Groenier KH; de Bruijn HW; Hollema H; ten Hoor KA; van der Zee AG; Aalders JG
J Clin Oncol; 1996 Jan; 14(1):111-8. PubMed ID: 8558185
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of pretreatment serum levels of squamous cell carcinoma antigen and CA 125 in cervical carcinoma.
Avall-Lundqvist EH; Sjövall K; Nilsson BR; Eneroth PH
Eur J Cancer; 1992; 28A(10):1695-702. PubMed ID: 1389488
[TBL] [Abstract][Full Text] [Related]
19. Squamous cell carcinoma antigen (SCC-Ag) during follow-up of cervical cancer patients: Role in the early diagnosis of recurrence.
Salvatici M; Achilarre MT; Sandri MT; Boveri S; Vanna Z; Landoni F
Gynecol Oncol; 2016 Jul; 142(1):115-119. PubMed ID: 27117922
[TBL] [Abstract][Full Text] [Related]
20. Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer.
Gaarenstroom KN; Bonfrer JM; Kenter GG; Korse CM; Hart AA; Trimbos JB; Helmerhorst TJ
Cancer; 1995 Sep; 76(5):807-13. PubMed ID: 8625184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
